ODiN
Request a feasibility assessmentRequest assessment
Orphan Drug Intelligence · Brazil & Latin America

Clinical development in Latin America, powered by intelligence.

ODiN combines CRO execution, proprietary clinical data and AI to help biotech and pharmaceutical companies run faster, smarter and higher-performing clinical trials in Brazil and Latin America.

Where are the patients? Which sites can actually recruit them? How feasible is the protocol? And how do we improve trial performance before enrolment becomes a problem?

200M+
public healthcare population
measured

Patients represented in Brazil's public healthcare data ecosystem.

7M+
clinically mapped patients
measured

Longitudinal hospital and clinical data, structured with proprietary NLP.

100M+
clinical notes processed
measured

Unstructured EHR narrative read by clinical NLP built for Brazilian records.

Clinical development experience trusted by global biotech and pharma

PfizerNovartisSobiBiogenIncyteRelayImmunocoreBioMarin
From protocol to patient

We don't start with a site list. We start with the patients.

Traditional feasibility often depends on questionnaires, investigator estimates and historical assumptions. ODiN adds another layer: real-world clinical intelligence.

Through iHealth's clinical data infrastructure, we analyse longitudinal patient journeys and unstructured EHR data using clinical NLP and AI — identifying characteristics that are often invisible in structured databases alone.

This takes feasibility past “Do you think this site can recruit?” to a question with an answer:

Can we find evidence that the patients are actually there?
Diagnoses and disease progressionBiomarkersPhenotypesComorbiditiesPrior and current therapiesTreatment linesLaboratory resultsProceduresClinical outcomesHospitalisationsPhysician notesNursing and multidisciplinary notesProtocol-specific characteristics
Eligibility, narrowed
Indication present in mapped data · 12.480Meets core inclusion c… · 3.21025.7% retainedBiomarker recorded and posi… · 1.14035.5% retainedWithin reach of a candidate site · 64056.1% retainedConsent-adjusted · 40062.5% retained
measuredderivedjudgement

Illustrative protocol. The stage counts are an example; the tiers are the real grammar — the consent-adjusted total is Judgement because that is the weakest input it rests on.

The ODiN advantage

Intelligence before execution. Intelligence throughout execution.

Three capabilities that have traditionally operated separately.

01

Data & AI

Proprietary clinical intelligence

Clinical NLP infrastructure that turns fragmented, unstructured healthcare data into structured clinical variables — developed specifically to read Brazilian medical records, including the free-text notes structured datasets miss.

  • Protocol feasibility
  • Patient population estimation
  • Biomarker identification
  • Patient journey reconstruction
  • Eligibility simulations
  • Protocol complexity assessment
  • Epidemiological analysis
  • Site selection
  • Recruitment planning
  • Real-world evidence
02

Sites & patient access

Connected to the institutions that treat the patients you need

Data intelligence paired with relationships across leading hospitals, physicians, research centres and referral institutions throughout Brazil and Latin America — and the specialists who see the patients before a trial ever does.

  • Rare diseases
  • Oncology
  • Neurology
  • Hematology
  • Ophthalmology
  • Endocrinology
  • Nephrology
  • Precision medicine
03

CRO execution

Intelligence is only valuable if it improves execution

iHealth's technology and clinical intelligence combined with ODC Life Sciences' delivery experience across Latin America — from country assessment through to enrolment.

  • Country & regional feasibility
  • Protocol feasibility
  • Site identification & selection
  • Site activation
  • Patient recruitment
  • Patient pre-screening
  • HCP & referral network activation
  • Patient & community engagement
  • Study performance intelligence
  • Real-world evidence
One partner, three intelligence layers

From population, to patient, to site, to trial.

Each layer narrows the one above it, and each is a different kind of evidence. The tier on a layer is the strongest claim anything drawn from it can make.

Population intelligence

200M+public healthcare population
measured

National epidemiological and healthcare-utilisation intelligence derived from Brazil's public health ecosystem.

Clinical intelligence

7M+clinically mapped patients
measured

Longitudinal hospital and clinical data analysed with proprietary NLP and healthcare AI.

Execution intelligence

Sitesinvestigators · patients
judgement

Trial operations, patient recruitment, referral networks and local execution across Brazil and Latin America.

From population → patient → site → trial.
Built for orphan and complex development

Rare patients are difficult to find. Their data should not be.

Rare disease development creates a fundamental problem: patients may exist — but they are frequently fragmented across institutions, misdiagnosed, undiagnosed, or described through clinical characteristics that never appear in a structured diagnosis field.

ODiN was created for this problem. Our clinical NLP analyses longitudinal EHR narratives and searches for combinations of symptoms, biomarkers, therapies, laboratory findings, phenotypes, procedures and disease progression to surface populations a database search overlooks.

Rare and ultra-rare diseases
Genetic disorders
Precision oncology
Biomarker-driven trials
Cell and gene therapies
Complex inclusion/exclusion criteria
Hard-to-recruit populations
Patient finding beyond ICD codes

An ICD code is usually only the beginning of the story.

Structured query

Diagnosis = Disease X

ODiN query

Symptoms+Biomarker+Age+Treatment history+Laboratory findings+Comorbidities+Disease progression+Prior procedures
Know before you go

Make Brazil a data-driven decision.

Before opening a country, a sponsor should be able to see its real potential. ODiN builds a Brazil Opportunity Assessment for a clinical development programme.

01

Disease landscape

Estimated and observed patient populations.

02

Patient distribution

Where relevant patients are likely to receive care.

03

Protocol simulation

Potential impact of inclusion and exclusion criteria.

04

Biomarker availability

Biomarker signals identified within available clinical data.

05

Patient journey

How patients move from symptoms to diagnosis, treatment and referral.

06

Site landscape

Relevant institutions, investigators and referral centres.

07

Recruitment potential

Evidence-based assessment of enrolment capacity.

08

Competitive landscape

Ongoing trials competing for the same patients.

09

Operational assessment

Regulatory, site and execution considerations.

Give sponsors evidence before they commit capital and time to a country.

Request a Brazil Opportunity Assessment
From intelligence to enrolment

Seven steps, and the first one is a protocol.

01

Share the protocol

Send ODiN a protocol, synopsis or target patient profile.

02

We structure the eligibility criteria

Clinical and data teams translate the protocol into searchable clinical variables.

03

We analyse the population

Proprietary clinical data, public healthcare intelligence, epidemiology and external datasets.

04

We map patients and referral pathways

Geographic concentration, relevant institutions, physicians and referral networks.

05

We recommend sites

Prioritised on patient evidence and operational capability, not reputation alone.

06

We execute

ODC's clinical operations infrastructure supports activation, recruitment and delivery.

07

We continuously learn

Recruitment and trial-performance data become signals that improve execution.

Every patient is a signal. ODiN finds where they converge.

A new model for feasibility

Evidence before estimates.

Traditional model

  1. Sponsor
  2. CRO
  3. Feasibility questionnaire
  4. Site
  5. Investigator estimate

“We believe we can recruit 5 patients.”

ODiN model

  1. Sponsor
  2. Patient population intelligence
  3. Protocol simulation
  4. Clinical NLP & RWD
  5. Site and referral mapping
  6. Investigator validation

CRO execution

Therapeutic expertise

Designed for programmes where finding the patient is the hard part.

Rare & orphan diseases

Find patients hidden across fragmented care pathways and complex medical histories.

Oncology & precision oncology

Tumour characteristics, biomarkers, treatment histories and lines of therapy.

Hematology

Complex hematologic profiles across specialised centres and referral pathways.

Neurology

Longitudinal patient journeys where diagnosis can take years.

Cell & gene therapy

Highly selective patient identification and specialised centre mapping.

Ophthalmology

Specialised investigators and populations for complex ophthalmic indications.

Endocrinology & metabolic

Rare and complex metabolic populations across healthcare networks.

Nephrology

Advanced and rare renal disease populations from longitudinal clinical information.

Built for biotech

Your next programme doesn't need another database. It needs an intelligence layer.

For emerging biotech, every development decision has consequences for runway.

The goal is not to open more sites. The goal is to make every site count.

Should Brazil be part of our next trial?

How many patients could realistically qualify?

Which centres actually see those patients?

Can we accelerate recruitment?

Which eligibility criteria create the greatest constraints?

Where are the referral networks?

How should we execute across LatAm?

Powered by two specialised organisations

Together, we are ODiN.

The capitalisation records the merger: ODC + iHealth.

Clinical data & AI

iHealth

Transforms real-world clinical data into actionable intelligence through proprietary clinical NLP, healthcare AI and a collaborative clinical data infrastructure — structuring longitudinal medical records for research, patient finding, RWE and epidemiology.

Data. AI. Evidence.

Clinical trial execution

ODC Life Sciences

Connects sponsors with investigators, research institutions and patient populations throughout Latin America — patient recruitment, site identification and activation, physician and community engagement across complex therapeutic areas.

Sites. Patients. Execution.

Find the patients.
Select the right sites.
Execute the trial.
Generate the evidence.

Bring us your hardest-to-find patient.

We built ODiN for the programmes where traditional feasibility is not enough. If you are evaluating Brazil or Latin America for an upcoming trial, send us your protocol or target patient profile.